Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
about
Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in KoreaCritical appraisal of eculizumab for atypical hemolytic uremic syndromeAdvances and challenges in the management of complement-mediated thrombotic microangiopathiesTailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis.Complement regulators in human disease: lessons from modern genetics.Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.An international consensus approach to the management of atypical hemolytic uremic syndrome in children.A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience.Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule.Thrombotic microangiopathy without renal involvement: two novel mutations in complement-regulator genes.Successful Renal Transplantation in a Patient with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab in ChinaC3:CH50 ratio as a proposed composite marker for eculizumab monitoring in atypical hemolytic uremic syndrome: Preliminary results.Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to EculizumabMonitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.A Case Report and Literature Review of Eculizumab Withdrawal in Atypical Hemolytic-Uremic SyndromeAtypical Hemolytic Uremic Syndrome: A Brief Review.Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literatureThe role of the complement system in cancer.Novel biomarker and easy to perform ELISA for monitoring complement inhibition in patients with atypical hemolytic uremic syndrome treated with eculizumab.Invasive meningococcal disease in three siblings with hereditary deficiency of the 8(th) component of complement: evidence for the importance of an early diagnosisA novel CD46 mutation in a patient with microangiopathy clinically resembling thrombotic thrombocytopenic purpura and normal ADAMTS13 activity.Long-term outcomes of the Atypical Hemolytic Uremic Syndrome after kidney transplantation treated with eculizumab as first choice.The genetic basis of seborrhoeic dermatitis: a review.Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update.Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome.Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action.Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis: comment
P2860
Q26739894-A211FC92-E939-473A-BCF1-284473F6BBCCQ26750692-9C0D2B5C-4C62-415D-AD21-003293081F55Q26796453-06A27397-2620-4AF3-92D6-54A986DB6D48Q33415999-BBE5CEAC-C1CB-49EC-9F71-1A4F8DBD9A25Q33419261-0DC73F41-F8C4-44C3-828A-B99D21CB022EQ33421669-DBAD9C38-9BB2-45DB-A630-8228A6D71C52Q33421861-EBAC1B43-7580-43EA-9175-F8A6432C150AQ33422224-15E548D4-B01C-4833-A7A6-8FA80D6ACB3AQ33425610-08B1D343-9CC9-4E64-B061-E2FC93F14EDBQ33427932-695F359D-9CBB-49C0-AE2B-84A78E5D0864Q33432544-D101D070-7BC3-476F-81A8-974A52B4A885Q33435310-7D63C853-EF91-4F60-9E06-FDE90F046231Q33436295-2A597A12-B0AC-4EC1-B168-D52FD1B7279CQ33436307-9DC47734-D76A-417C-8E86-7C450EB3B6CBQ33437634-0EB7B2E0-2698-4058-B04C-6DF2FB821F61Q33442794-E4118E12-1E57-449E-A120-6B3AA163ECEDQ38927860-2B95222E-4240-40B6-A6C3-BDD60011B90DQ39156024-19781716-4EB1-48C6-A157-60F2BC06B356Q40654455-AA0515EB-9D2F-4710-A696-55D36BE8028CQ40672986-9DFF1624-74E3-486C-A579-D4895FF2536FQ43175189-CAA9D59C-77CB-46E3-897D-D9AC4E8CF537Q47129863-D616BB45-1EFE-437E-914E-BBDFC121E8C2Q47387957-3E157E03-7E10-433C-8265-DFFD75F73411Q47605517-22419C60-4E07-40E9-B2ED-31B54451C5ADQ50660833-148B8654-AADD-4F47-82AD-90179D8CB4CDQ52323527-C311F972-E80B-455C-A508-C1DF81BA4FC6Q58418354-F3D0B66B-82A8-4551-B0CA-1BB9FBC4BCF0
P2860
Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Complement functional tests fo ...... cal hemolytic uremic syndrome.
@ast
Complement functional tests fo ...... cal hemolytic uremic syndrome.
@en
type
label
Complement functional tests fo ...... cal hemolytic uremic syndrome.
@ast
Complement functional tests fo ...... cal hemolytic uremic syndrome.
@en
prefLabel
Complement functional tests fo ...... cal hemolytic uremic syndrome.
@ast
Complement functional tests fo ...... cal hemolytic uremic syndrome.
@en
P2093
P2860
P50
P356
P1476
Complement functional tests fo ...... cal hemolytic uremic syndrome.
@en
P2093
D Cresseri
E Grovetti
G Ardissino
I Possenti
S Griffini
S Tedeschi
P2860
P304
P356
10.1111/JTH.12615
P577
2014-07-16T00:00:00Z